Geneva, June 22 -- International Clinical Trials Registry received information related to the study (KCT0012121) titled 'Pharmacokinetic and Safety Study of Rivaroxaban in Elderly Subjects with and without Renal Impairment' on June 12.
Study Type: Interventional Study
Study Design:
Primary Purpose : Basic Science, Intervention Model : Parallel, Blinding/Masking : Open, Allocation : Non-RCT
Primary Sponsor: The Catholic University of Korea, Seoul St. Mary's Hospital
Condition:
Factors influencing health status and contact with health services
Intervention:
Drug : The study drug is Hanmi Riroxban Tablet (rivaroxaban), administered as a single oral dose with 150 mL of room-temperature water within 30 minutes after a meal on the morn...